Roivant Q2: LISRAYA Hits $31M in First 5 Weeks; IMVT-1402 Wins D2T RA Endpoint
ROIV has more than doubled off its 52-week low of $19.79.
Summary
Roivant's second quarter delivered $31.0 million of LISRAYA revenue in the drug's first five weeks and a positive IMVT-1402 rheumatoid arthritis endpoint, backed by $4.2 billion in cash. The net loss widened to $191.6 million, largely on non-cash Genevant distributions.
Key Events · Earnings and Guidance · ROIV
-
LISRAYA Books $31.0M in First Five Weeks
Net product revenue of $31.0 million for the three months ended September 30, 2026, all from LISRAYA's first five weeks of U.S. launch after the August 2026 FDA approval.
-
IMVT-1402 Meets D2T RA Endpoint at 600 mg
ACR20 response at Week 28 was 92.5% vs 75.6% for placebo (p=0.0139); the 300 mg arm showed no separation (75.0%, p=0.9426). FDA discussions are planned for later this year on the registrational path.
-
Sjogren's Program Effectively Shelved
Citing the evolving Sjogren's disease landscape and recent field data, Roivant expects it is unlikely to advance IMVT-1402 beyond the ongoing, fully enrolled Phase 2 trial in that indication.
-
Loss Widens on Non-Cash Genevant Charge
Net loss attributable to Roivant was $191.6 million, or $0.27 per share, including $95.9 million of distributions on Genevant RSUs and options that participated in the Moderna settlement proceeds — a $0.13 per-share drag.
Analysis · ROIV · Life Sciences
The quarter's headline is commercial: LISRAYA (brepocitinib) booked $31.0 million of net product revenue in its first five weeks on the market, the first real read on whether the August dermatomyositis approval converts into sales. Equally important is the clinical update — IMVT-1402 600 mg met the primary ACR20 endpoint in difficult-to-treat rheumatoid arthritis (92.5% vs 75.6% placebo, p=0.0139), though the 300 mg dose did not separate from placebo and the company now expects it is unlikely to push the drug further in Sjogren's disease. Against that, the balance sheet remains the story: $4.2 billion of cash and securities supports runway into profitability, and the company bought back 2.1 million shares for about $72.5 million in the quarter. The loss widened to $191.6 million, but $95.9 million of that is non-cash Genevant RSU/option distributions tied to the Moderna settlement proceeds. Next checkpoint is the December 9 Investor Day.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $41.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1B. The 52-week trading range was $19.79 to $42.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.